000275458 001__ 275458
000275458 005__ 20240229154941.0
000275458 0247_ $$2doi$$a10.1016/j.ejca.2023.03.019
000275458 0247_ $$2pmid$$apmid:37068406
000275458 0247_ $$2ISSN$$a0014-2964
000275458 0247_ $$2ISSN$$a0959-8049
000275458 0247_ $$2ISSN$$a1879-0852
000275458 0247_ $$2ISSN$$a(1990)
000275458 0247_ $$2ISSN$$a1879-2995
000275458 0247_ $$2ISSN$$a(1965)
000275458 0247_ $$2altmetric$$aaltmetric:146020030
000275458 037__ $$aDKFZ-2023-00773
000275458 041__ $$aEnglish
000275458 082__ $$a610
000275458 1001_ $$aTichanek, Filip$$b0
000275458 245__ $$aSurvival in melanoma in the nordic countries into the era of targeted and immunological therapies.
000275458 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2023
000275458 3367_ $$2DRIVER$$aarticle
000275458 3367_ $$2DataCite$$aOutput Types/Journal article
000275458 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1681817634_19399
000275458 3367_ $$2BibTeX$$aARTICLE
000275458 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275458 3367_ $$00$$2EndNote$$aJournal Article
000275458 500__ $$a#LA:C020#
000275458 520__ $$aSurvival in melanoma has been increasing and the most recent interest is to observe the population-level impact of novel targeted therapies and immunotherapy. We analysed survival in melanoma from Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE) over a 50-years period (1971-2020).Relative 1-5/1- and 5-year survival data were obtained from the NORDCAN database for the years 1971-2020. We estimated annual changes in survival rates and determined significant breaking points for trends.Survival in melanoma has reached the point where 1-year survival is approaching 100% (men 97.5-98.6%, women 98.4-99.3%, depending on the country) and 5-year survival is 93% for men (91.5-95.2%) and 96% for women (95.3-97.2%). The highest survival figures were for DK. Significant increases in both 1- and 5-year survival were observed in most countries even towards the end of the follow-up (from 2006 to 2010-2011-2015 and further to 2016-2020).The main increase in melanoma survival took place up to year 1990, which was probably largely achieved through successful population campaigns for sun protection and programmes for early detection of lesions. Survival increased again after year 2000 up to the last period 2016-2020. This late development coincided with the introduction of targeted therapies using BRAF and BRAF/MEK inhibitors, and towards the end of the time period availability of checkpoint inhibitors. The success of melanoma treatment in DK was mostly likely due to the efficient use of modern therapies and to the centralised treatment for metastatic disease.
000275458 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000275458 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000275458 650_7 $$2Other$$aConditional survival
000275458 650_7 $$2Other$$aImmunotherapy
000275458 650_7 $$2Other$$aRelative survival
000275458 650_7 $$2Other$$aSun protection
000275458 650_7 $$2Other$$aTargeted therapy
000275458 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b1$$udkfz
000275458 7001_ $$aHemminki, Akseli$$b2
000275458 7001_ $$aHemminki, Otto$$b3
000275458 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b4$$eLast author$$udkfz
000275458 773__ $$0PERI:(DE-600)1468190-0$$a10.1016/j.ejca.2023.03.019$$gVol. 186, p. 133 - 141$$p133 - 141$$tEuropean journal of cancer$$v186$$x0014-2964$$y2023
000275458 909CO $$ooai:inrepo02.dkfz.de:275458$$pVDB
000275458 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000275458 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000275458 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000275458 9141_ $$y2023
000275458 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-30
000275458 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-30
000275458 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-30
000275458 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000275458 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000275458 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000275458 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000275458 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000275458 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000275458 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000275458 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000275458 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J CANCER : 2022$$d2023-10-21
000275458 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000275458 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000275458 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J CANCER : 2022$$d2023-10-21
000275458 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000275458 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000275458 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x1
000275458 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000275458 980__ $$ajournal
000275458 980__ $$aVDB
000275458 980__ $$aI:(DE-He78)B062-20160331
000275458 980__ $$aI:(DE-He78)C020-20160331
000275458 980__ $$aI:(DE-He78)HD01-20160331
000275458 980__ $$aUNRESTRICTED